**Question:** Drug of choice for paracoccidioidomycosis is

A. Amphotericin B
B. Itraconazole
C. Fluconazole
D. Posaconazole

**Correct Answer:** B. Itraconazole

**Core Concept:** Paracoccidioidomycosis is a systemic mycosis caused by the fungus Paracoccidioides spp., primarily affecting the lungs in endemic areas. It is typically treated with antifungal medications targeting the fungal cell wall.

**Why the Correct Answer is Right:** Itraconazole (ITZ) is a triazole antifungal drug that inhibits the enzyme lanosterol 14α-demethylase (Erg11p), a key enzyme in ergosterol biosynthesis of fungal cells. By inhibiting this enzyme, ITZ disrupts the synthesis of ergosterol, leading to accumulation of toxic precursors, membrane instability, and ultimately cell death in the fungal pathogens like Paracoccidioides spp. responsible for paracoccidioidomycosis.

**Why Each Wrong Option is Incorrect:**

A. Amphotericin B (AMB): AMB is a polyene antifungal medication that forms a complex with ergosterol in the fungal cell membrane, disrupting its integrity and causing cell death. However, AMB is not a first-line therapy for paracoccidioidomycosis due to its nephrotoxicity and hemolysis risks.

C. Fluconazole (FLCZ): FLCZ is another triazole antifungal drug with similar mechanism of action to ITZ but has lower potency against Paracoccidioides spp. and is generally reserved for oral therapy or in combination with ITZ.

D. Posaconazole (POS): POS is another triazole antifungal drug that inhibits ergosterol biosynthesis but is less potent than ITZ and is not the preferred choice for paracoccidioidomycosis treatment.

**Clinical Pearl:** Due to its potency, safety profile, and oral availability, ITZ is the first-line antifungal medication for paracoccidioidomycosis treatment. This allows for systemic therapy, reducing the risk of nephrotoxicity and other complications associated with AMB.